Once-daily ciclesonide via metered-dose inhaler: Similar efficacy and safety with or without a spacer

Respiratory Medicine

Volumn 103, Issue 11, 2009, Pages 1643-1650

  Engelstätter, Renate ^a   Szlavik M ^b   Gerber, Claudia ^a   Beck, Ekkehard ^c  

^a Nycomed GmbH   (Germany)

^b Hosp for Chest Dis of Somogy Co   (Hungary)

^c Institut für Gesundheitsförderung GmbH   (Germany)

Author keywords

Asthma; Ciclesonide; Metered dose inhaler; Spacer device

Indexed keywords

CICLESONIDE; FLUORINATED HYDROCARBON;

ADULT; ARTICLE; ASTHMA; CHOLANGITIS; CHRONIC PANCREATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSIVE CRISIS; INHALATION SPACER; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; OSTEOTOMY; PANCREAS CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPONTANEOUS ABORTION; SYMPTOM;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; ASTHMA; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; PREGNENEDIONES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349479178     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.06.004     Document Type: Article

References (25)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available at: (2007). www.ginasthma.com [accessed 25.07.08]
2. Humbert M. The right tools at the right time. Chest 130 1 Suppl. (2006) 29S-40S
3. National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program. Expert panel report 3: guidelines for the diagnosis and management of asthma (2007). www.nhlbi.nih.gov [accessed 25.07.08]
4. Jackson L.D., Polygenis D., McIvor R.A., and Worthington I. Comparative efficacy and safety of inhaled corticosteroids in asthma. Can J Clin Pharmacol 6 1 (1999) 26-37
5. Newman S.P. Spacer devices for metered dose inhalers. Clin Pharmacokinet 43 6 (2004) 349-360
6. Brown P.H., Matusiewicz S.P., Shearing C., Tibi L., Greening A.P., and Crompton G.K. Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. Thorax 48 10 (1993) 967-973
7. Goldberg S., Einot T., Algur N., et al. Adrenal suppression in asthmatic children receiving low-dose inhaled budesonide: comparison between dry powder inhaler and pressurized metered-dose inhaler attached to a spacer. Ann Allergy Asthma Immunol 89 6 (2002) 566-571
8. Hubner M., Hochhaus G., and Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am 25 3 (2005) 469-488
9. Newman S., Salmon A., Nave R., and Drollmann A. High lung deposition of (99m)Tc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 100 3 (2006) 375-384
10. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 47 6 (2007) 782-789
11. Drollmann A., Nave R., Steinijans V.W., Baumgartner E., and Bethke T.D. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber Plus spacer for inhalation. Clin Pharmacokinet 45 7 (2006) 729-736
12. The European Agency for the Evaluation of Medicinal Products (EMEA). Committee for the proprietary medicinal products. Points to consider on the requirements for clinical documentation for orally inhaled products (2004). www.emea.europa.eu/pdfs/human/ewp/415100en.pdf [accessed 28.07.08]
13. European Medicines Agency (EMEA). Committee for medicinal products for human use. Guideline on the pharmaceutical quality of inhalation and nasal products (2006). www.emea.europa.eu/pdfs/human/qwp/4931305en.pdf [accessed 28.07.08]
14. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available at (2004). www.ginasthma.com [accessed 25.07.08]
15. American Thoracic Society. Standardization of spirometry - 1994 Update. Am J Respir Crit Care Med 152 (1995) 1107-1136
16. Ebbutt A., and Frith L. Practical issues in equivalence trials. Statistical Methods 17 (1998) 1691-1701
17. Milliken G., and Johnson D. Analysis of messy data: analysis of covariance vol. III (2002), Chapman and Hall/CRC, Boca Raton, Washington
18. van Elteren P. On the combination of independent two samples tests of Wilcoxon. Bull Int Stat Inst 37 (1960) 351-361
19. Global Initiative for Asthma. Global strategy for asthma management and prevention. Available from: (2006). www.ginasthma.com [accessed 25.07.08]
20. Magnussen H., Hofman J., Staneta P., Lawo J.P., Hellwig M., and Engelstatter R. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. J Asthma 44 7 (2007) 555-563
21. Pedersen S., Garcia Garcia M.L., Manjra A., Theron I., and Engelstatter R. A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 41 10 (2006) 954-961
22. Langdon C.G., Adler M., Mehra S., Alexander M., and Drollmann A. Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 99 10 (2005) 1275-1285
23. Bateman E.D., Linnhof A.E., Homik L., Freudensprung U., Smau L., and Engelstätter R. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 21 2 (2008) 264-275
24. Boulet L.P., Bateman E.D., Voves R., Muller T., Wolf S., and Engelstatter R. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 101 8 (2007) 1677-1686
25. Engelstätter R., Escher A., and Haefner D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J 26 Suppl. 49 (2005) 255s